Industry News
Share your love
Melt Pharma Raises $24M for Sedation Tablet
Melt Pharmaceuticals has successfully completed a significant financial milestone, securing approximately $24 million through its Series B Preferred Stock financing round. This latest funding round saw contributions from both new and returning investors, setting the stage for the accelerated development…
Pantheon Vision Gets Another $1.8M for Corneal Implants
Pantheon Vision, a pioneering medical device company in the pre-clinical stage focused on developing bioengineered corneal implants, has secured an additional $1.8 million in funding. This recent financial boost is part of a second tranche from KeraLink International (KLI), following…
CSI Dry Eye Software Unveils Version 5.0 Update
CSI Dry Eye Software, a leading innovator in the field of artificial intelligence for eye care, has officially announced the release of its latest software update, Version 5.0. This update marks a significant leap forward in the company’s mission to…
Viatris Launches RYZUMVI™ 0.75% in the United States
Viatris Inc. announced the commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% in the United States. This treatment is the only FDA-approved eye drop available in the U.S. market designed to reverse pharmacologically-induced mydriasis, commonly caused by adrenergic agonists like…
Alcon Names Terry Kim, MD as Chief Medical Officer
Alcon announced the appointment of Terry Kim, MD, as the company’s new Chief Medical Officer (CMO) and Head of Global Medical Safety, starting in April. Dr. Kim, a renowned figure in the field of ophthalmology, brings a wealth of experience…
Aldeyra Eyes NDA Resubmission for DED Treatment
Aldeyra Therapeutics announced its clinical development strategy aimed at the resubmission of a New Drug Application (NDA) for its topical ocular 0.25% reproxalap. This investigational RASP modulator is poised for the treatment of dry eye disease, pending approval from the…
ASCRS Congress 2024 Set to Take Place in April 5-8
From April 5 to 8, 2024, the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting is set to take place in Boston, USA, at the Boston Convention & Exhibition Center. This annual meeting is a pivotal event for…
ABVC BioPharma and ForSeeCon Ink Global Agreement
ABVC BioPharma, Inc. has entered into a significant global licensing agreement with ForSeeCon Eye Corporation (FEYE), marking a pivotal moment for the clinical-stage biopharmaceutical company known for its developments in ophthalmology, CNS, and oncology The agreement focuses on ABVC’s ophthalmology…
Iveric Bio Secures Key J-code for GA Therapy, Izervay
In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, a subsidiary of Astellas Pharma, has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for…
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…